Year: 2023

cemagraphics ETFs are a great way to gain automatic diversification, and for many investors, this comes with a peace of mind in not having to trade the market day in and day out and second […]

Wagner Meier A little more than a year ago, slightly agitated by the way the market has approached the question of valuing the Brazilian oil and gas giant, we wrote an article pointing out what […]

sunnychicka/iStock via Getty Images Former biosimilar-only developer Coherus Biosciences (NASDAQ:CHRS) went into business with Chinese partner Junshi to develop toripalimab, an anti-PD-1 antibody that had a PDUFA date on December 23 targeting first-line treatment for […]